HUTCHMED (China) Limited (HK:0013) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HUTCHMED (China) Limited has announced that its combination therapy of ORPATHYS® and TAGRISSO® has received Breakthrough Therapy Designation in China for certain lung cancer patients. This designation by China’s National Medical Products Administration highlights the potential of this combination to address unmet medical needs in patients with advanced or metastatic non-small cell lung cancer with MET amplification. The therapy is currently being tested in Phase III trials, aiming to offer a chemotherapy-free treatment option.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.